Moreover, blocking the VEGF-C signal using a VEGF-C neutralizing antibody (pV1006R-r) significantly reduced the LNMAT1-transduced tumor burden in the lymph nodes (Fig. 8f, g), suggesting that blocking VEGF-C signaling abrogated the LNMAT1-induced lymphatic metastasis in vivo. Here, DUXAP9 is linked to neoplasm.